scholarly journals Antiangiogenic Therapy in Epithelial Ovarian Cancer

10.5772/60822 ◽  
2016 ◽  
Author(s):  
M.A. Alonso Bermejo ◽  
L. Rey Iglesias ◽  
M.E. Pérez López ◽  
A. Fernández Montes ◽  
J. García Mata
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Antiangiogenic Therapy

scholarly journals AIM2 Inflammasome in Tumor Cells as a Biomarker for Predicting the Treatment Response to Antiangiogenic Therapy in Epithelial Ovarian Cancer Patients

2021 ◽  
Vol 10 (19) ◽  
pp. 4529
Author(s):  
Po-Chao Hsu ◽  
Tai-Kuang Chao ◽  
Yu-Ching Chou ◽  
Mu-Hsien Yu ◽  
Yu-Chi Wang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Treatment Response ◽  
Antiangiogenic Therapy ◽  
Progression Free Survival ◽  
Mean Value ◽  
Complement Component ◽  
Risk Patients ◽  
High Level ◽  
Serous Papillary Carcinoma

Antiangiogenic therapy, such as bevacizumab (BEV), has improved progression-free survival (PFS) and overall survival (OS) in high-risk patients with epithelial ovarian cancer (EOC) according to several clinical trials. Clinically, no reliable molecular biomarker is available to predict the treatment response to antiangiogenic therapy. Immune-related proteins can indirectly contribute to angiogenesis by regulating stromal cells in the tumor microenvironment. This study was performed to search biomarkers for prediction of the BEV treatment response in EOC patients. We conducted a hospital-based retrospective study from March 2013 to May 2020. Tissues from 78 Taiwanese patients who were newly diagnosed with EOC and peritoneal serous papillary carcinoma (PSPC) and received BEV therapy were collected. We used immunohistochemistry (IHC) staining and analyzed the expression of these putative biomarkers (complement component 3 (C3), complement component 5 (C5), and absent in melanoma 2 (AIM2)) based on the staining area and intensity of the color reaction to predict BEV efficacy in EOC patients. The immunostaining scores of AIM2 were significantly higher in the BEV-resistant group (RG) than in the BEV-sensitive group (SG) (355.5 vs. 297.1, p < 0.001). A high level of AIM2 (mean value > 310) conferred worse PFS after treatment with BEV than a low level of AIM2 (13.58 vs. 19.36 months, adjusted hazard ratio (HR) = 4.44, 95% confidence interval (CI) = 2.01–9.80, p < 0.001). There were no significant differences in C3 (p = 0.077) or C5 (p = 0.326) regarding BEV efficacy. AIM2 inflammasome expression can be a histopathological biomarker to predict the antiangiogenic therapy benefit in EOC patients. The molecular mechanism requires further investigation.

Antiangiogenic Agents in Combination With Chemotherapy for the Treatment of Epithelial Ovarian Cancer

2012 ◽  
Vol 22 (3) ◽  
pp. 348-359 ◽  
Author(s):  
Deanna Teoh ◽  
Angeles Alvarez Secord
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Treatment Strategy ◽  
Kinase Inhibitors ◽  
Antiangiogenic Therapy ◽  
Single Agent ◽  
Clinical Trial Data ◽  
Optimal Dose ◽  
Dose Schedule ◽  
Antiangiogenic Agents

ObjectiveThe purpose of this review was to provide an overview of angiogenesis, including the rationale for targeting angiogenesis as a treatment strategy for epithelial ovarian cancer (EOC) and to discuss available clinical trial data with antiangiogenic agents in EOC, with a focus on combinations with chemotherapy.MethodsThis was a literature review of clinical studies evaluating select antiangiogenic agents in combination with traditional cytotoxic chemotherapy for the treatment of EOC.ResultsSeveral therapies that target angiogenesis-specific pathways are undergoing clinical development for EOC. Although some of these agents have demonstrated single-agent activity for EOC, there is considerable interest in combining this treatment strategy with chemotherapy in an effort to potentially improve treatment benefits in this patient population. Bevacizumab, an anti–vascular endothelial growth factor (VEGF) monoclonal antibody, is the most studied antiangiogenic agent in EOC and has shown efficacy as monotherapy and combined with chemotherapy in both the relapsed/recurrent and first-line settings. However, results from recent phase 3 trials raise questions regarding patient selection and optimal dose, schedule, and duration of bevacizumab therapy. Other agents in various phases of testing include aflibercept (VEGF Trap), a fusion protein that binds all isoforms of VEGF; multitargeted antiangiogenic tyrosine kinase inhibitors (eg, BIBF 1120, cediranib, pazopanib, sorafenib); and AMG 386, a selective angiopoietin inhibitor. Toxicities associated with VEGF inhibition are also a concern with antiangiogenic therapy, including hypertension, proteinuria, thromboses, and gastrointestinal perforation.ConclusionsResults from recently completed and ongoing clinical trials combining antiangiogenic agents with chemotherapy are awaited in hopes of expanding therapeutic options for patients with EOC.

Impact of extended cycles of chemotherapy on survival outcome in recurrent epithelial ovarian cancer

2020 ◽  
Vol 159 ◽  
pp. 346-347
Author(s):  
W.Y. Hwang ◽  
S.I. Kim ◽  
M. Lee ◽  
K. Kim ◽  
J.H. No ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Survival Outcome

Die personalisierte Therapie beim Ovarialkarzinom

2018 ◽  
Vol 39 (03) ◽  
pp. 180-186
Author(s):  
Ann-K. Langner ◽  
Nina Pauly ◽  
Beyhan Ataseven ◽  
Andreas du Bois
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Personalisierte Medizin ◽  
Personalisierte Therapie

Die Behandlung des epithelialen Ovarial-, Tuben- und Peritonealkarzinoms (epithelial ovarian cancer; EOC) fußt auf 3 Säulen, die in unterschiedlichem Maße individualisierte bzw. personalisierte Medizin inkludieren:

BCL6 function and platin resistance in epithelial ovarian cancer

2018 ◽  
Author(s):  
M Eberhardt ◽  
N Häfner ◽  
D Kritsch ◽  
M Rengsberger ◽  
M Dürst ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer
Sign in / Sign up

Export Citation Format

Share Document